BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30171229)

  • 21. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
    Pritchard CC; Mateo J; Walsh MF; De Sarkar N; Abida W; Beltran H; Garofalo A; Gulati R; Carreira S; Eeles R; Elemento O; Rubin MA; Robinson D; Lonigro R; Hussain M; Chinnaiyan A; Vinson J; Filipenko J; Garraway L; Taplin ME; AlDubayan S; Han GC; Beightol M; Morrissey C; Nghiem B; Cheng HH; Montgomery B; Walsh T; Casadei S; Berger M; Zhang L; Zehir A; Vijai J; Scher HI; Sawyers C; Schultz N; Kantoff PW; Solit D; Robson M; Van Allen EM; Offit K; de Bono J; Nelson PS
    N Engl J Med; 2016 Aug; 375(5):443-53. PubMed ID: 27433846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.
    Kimura H; Mizuno K; Shiota M; Narita S; Terada N; Fujimoto N; Ogura K; Hatano S; Iwasaki Y; Hakozaki N; Ishitoya S; Sumiyoshi T; Goto T; Kobayashi T; Nakagawa H; Kamoto T; Eto M; Habuchi T; Ogawa O; Momozawa Y; Akamatsu S
    Br J Cancer; 2022 Nov; 127(9):1680-1690. PubMed ID: 35986085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
    Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
    Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline DNA Damage Response Gene Mutations in Localized Prostate Cancer.
    Januskevicius T; Vaicekauskaite I; Sabaliauskaite R; Matulevicius A; Vezelis A; Ulys A; Jarmalaite S; Jankevicius F
    Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256334
    [No Abstract]   [Full Text] [Related]  

  • 26. Distinct Genomic Alterations in Prostate Tumors Derived from African American Men.
    Liu W; Zheng SL; Na R; Wei L; Sun J; Gallagher J; Wei J; Resurreccion WK; Ernst S; Sfanos KS; Isaacs WB; Xu J
    Mol Cancer Res; 2020 Dec; 18(12):1815-1824. PubMed ID: 33115829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
    Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
    Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Application of next-generation sequencing in detection of BRCA1/2 and homologous recombination repair pathway multi-genes germline mutation and correlation analysis].
    Chen YL; Zhuo ZL; Liu C; Xie F; Yang ZY; Liu PF; Wang S; Zhao XT
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Mar; 56(3):302-311. PubMed ID: 35381651
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
    Mahal BA; Yang DD; Wang NQ; Alshalalfa M; Davicioni E; Choeurng V; Schaeffer EM; Ross AE; Spratt DE; Den RB; Martin NE; Mouw KW; Orio PF; Choueiri TK; Taplin ME; Trinh QD; Feng FY; Nguyen PL
    Eur Urol; 2018 Aug; 74(2):146-154. PubMed ID: 29478736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
    Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S
    Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
    White JA; Kaninjing ET; Adeniji KA; Jibrin P; Obafunwa JO; Ogo CN; Mohammed F; Popoola A; Fatiregun OA; Oluwole OP; Karanam B; Elhussin I; Ambs S; Tang W; Davis M; Polak P; Campbell MJ; Brignole KR; Rotimi SO; Dean-Colomb W; Odedina FT; Martin DN; Yates C
    Cancer Res Commun; 2022 Sep; 2(9):1005-1016. PubMed ID: 36922933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
    Domagala P; Jakubowska A; Jaworska-Bieniek K; Kaczmarek K; Durda K; Kurlapska A; Cybulski C; Lubinski J
    PLoS One; 2015; 10(6):e0130393. PubMed ID: 26083025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
    Petrovics G; Price DK; Lou H; Chen Y; Garland L; Bass S; Jones K; Kohaar I; Ali A; Ravindranath L; Young D; Cullen J; Dorsey TH; Sesterhenn IA; Brassell SA; Rosner IL; Ross D; Dahut W; Ambs S; Figg WD; Srivastava S; Dean M
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):406-410. PubMed ID: 30542053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.
    Swift SL; Lang SH; White H; Misso K; Kleijnen J; Quek RG
    Future Oncol; 2019 Oct; 15(28):3283-3303. PubMed ID: 31535940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of BRCA2 Mutated Prostate Cancer at Presentation.
    Han H; Park CK; Cho NH; Lee J; Jang WS; Ham WS; Choi YD; Cho KS
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer.
    Darst BF; Dadaev T; Saunders E; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Gapstur SM; Stevens V; Albanes D; Weinstein SJ; Gnanapragasam V; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz M; Schmidt JA; Mucci L; Catalona WJ; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Kote-Jarai Z; Conti DV; Haiman CA
    J Natl Cancer Inst; 2021 May; 113(5):616-625. PubMed ID: 32853339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
    Caster JM; Falchook AD; Hendrix LH; Chen RC
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.
    Muralidhar V; Dinh KT; Mahal BA; Ziehr DR; Chen YW; Viswanathan VB; Nezolosky MD; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Trinh QD; Nguyen PL
    Urol Oncol; 2015 Jul; 33(7):330.e19-25. PubMed ID: 25990612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.